title: In vitro antimalarial activity of ICL670: a further proof of the correlation between inhibition of β-hematin formation and of peroxidative degradation of hemin.
abstract: Iron chelators such as deferiprone, deferoxamine (DFO) and ICL670 (deferasirox) have previously been shown to display in vitro and/or in vivo antimalarial activities. To gain further insight in their antimalarial mechanism of action, their activities on inhibition of β-hematin formation and on both peroxidative and glutathione (GSH)-mediated degradation of hemin were investigated. Neither deferiprone nor DFO were able to inhibit β-hematin formation while ICL670 activity nearly matched that of chloroquine (CQ). Peroxidative degradation of hemin was also only strongly inhibited by both CQ and ICL670, the latter being significantly more efficient at pH 5.2. All iron chelators displayed minor, if any, inhibitory activity on GSH-mediated degradation of hemin. Discrepancies in the results obtained for the three iron chelators show that iron chelation is not the main driving force behind interference with heme degradation. Deferiprone, DFO and ICL670 share little structural community but both ICL670 and antimalarial ursolic acid derivatives (previously shown to block β-hematin formation and the peroxidative degradation of hemin) have hydrophobic groups and hydroxyphenyl moieties. These similarities in structures and activities further back up a possible two-step mechanism of action previously proposed for ursolic acid derivatives (Mullié et al., 2010) implying (1) stacking of an hydrophobic structure to hemin and (2) additive protection of hemin ferric iron from H(2)O(2) by hydroxyphenyl groups through steric hindrance and/or trapping of oxygen reactive species in the direct neighborhood of ferric iron. These peculiar antimalarial mechanisms of action for ICL670 warrant further investigations and development.
authors.affiliation: Laboratoire des Glucides, équipe THERA, UMR-CNRS 6219, Faculté de Pharmacie, 1 rue des Louvels, Amiens Cedex 1, France.
authors.forename: P
authors.initials: P
authors.lastname: Sonnet
authors.forename: C
authors.initials: C
authors.lastname: Mullié
mesh_terms: D000962:Antimalarials / Q000737:chemistry / Q000494:pharmacology*; D001565:Benzoates / Q000737:chemistry / Q000494:pharmacology*; D002738:Chloroquine / Q000494:pharmacology; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000494:pharmacology; D005978:Glutathione / Q000378:metabolism; D006420:Hemeproteins / Q000096:biosynthesis / Q000187:drug effects*; D006427:Hemin / Q000378:metabolism*; D006861:Hydrogen Peroxide / Q000378:metabolism; D020128:Inhibitory Concentration 50; D007502:Iron Chelating Agents / Q000737:chemistry / Q000494:pharmacology*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000378:metabolism; D011728:Pyridones / Q000494:pharmacology; D013329:Structure-Activity Relationship; D014230:Triazoles / Q000737:chemistry / Q000494:pharmacology*; D014315:Triterpenes / Q000737:chemistry / Q000494:pharmacology; D000097245:Ursolic Acid
chemical_list: D000962:Antimalarials; D001565:Benzoates; D002738:Chloroquine; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine; D005978:Glutathione; D006420:Hemeproteins; D006427:Hemin; D006861:Hydrogen Peroxide; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D014315:Triterpenes; D000097245:Ursolic Acid; C020753:hemozoin